Trospium chloride

Trospium chloride

Clinical data
Trade names	Regurin, Sanctura, many generics
AHFS/Drugs.com	Monograph
Pregnancy category	C
Routes of administration	By mouth (tablets, capsules)
ATC code	G04BD09 (WHO)
Legal status
Legal status	In general: ℞ (Prescription only)
Pharmacokinetic data
Protein binding	50–85%
Biological half-life	20 hours
Identifiers
IUPAC name 3‑(2‑Hydroxy-2,2‑diphenylacetoxy)spiro[bicyclo[3.2.1]octane-8,1'‑pyrrolidin]-1'‑ium chloride
CAS Number	10405-02-4
PubChem CID	107979
DrugBank	DB00209
ChemSpider	10482307 Y
UNII	1E6682427E
ChEMBL	CHEMBL1201344
ECHA InfoCard	100.030.784
Chemical and physical data
Formula	C25H30ClNO3
Molar mass	427.964 g/mol
3D model (JSmol)	Interactive image
SMILES OC(c1ccccc1)(c2ccccc2)C(=O)O[C@@H]3C[C@@H]5CC[C@H](C3)[N+]45CCCC4
InChI InChI=1S/C25H30NO3/c27-24(25(28,19-9-3-1-4-10-19)20-11-5-2-6-12-20)29-23-17-21-13-14-22(18-23)26(21)15-7-8-16-26/h1-6,9-12,21-23,28H,7-8,13-18H2/q+1/t21-,22+,23+ Y Key:OYYDSUSKLWTMMQ-JKHIJQBDSA-N Y

Trospium chloride (INN) is used to treat overactive bladder.

It has side effects typical of drugs like it, namely dry mouth, stomach upset, and constipation; these side effects cause problems with people taking their medicine as directed. However it doesn't cause central nervous system side effects like other drugs of its class. It is pregnancy category C and is excreted somewhat in breast milk.

Chemically it is a quaternary ammonium cation which causes it to stay in periphery rather than crossing the blood-brain barrier. It works by causing the smooth muscle in the bladder to relax.

It was invented in the late 1960s in Germany and was first approved in Europe in 1999. It was first approved in the US in 2004, and an extended release version with once a day dosing was brought to market in 2007. It became generic in Europe in 2009 and in the US the first extended-release generic was approved in 2012.

Trospium chloride is used for the treatment of overactive bladder with symptoms of urge incontinence and frequent urination.

It shouldn't be used with people who retain urine, who have severe digestive conditions, myasthenia gravis, narrow-angle glaucoma, or tachyarrhythmia.

It should be used in caution with people who have problems with their autonomous nervous system (dysautonomia) or who have gastroesophageal reflux disease, or in whom fast heart rates are undesirable, such as people with hyperthyroidism, coronary artery disease and congestive heart failure.